Skip to content

Dr. Gearóid Tuohy

Research published in The Lancet, the New England Journal of Medicine, and the Journal of the American Medical Association may be barred by the US Department of Health & Human Services (HHS).

Mr. Robert F. Kennedy Jr., United States Secretary of Health & Human Services (HHS), has stated that government scientists who publish in a number of… Read More »Research published in The Lancet, the New England Journal of Medicine, and the Journal of the American Medical Association may be barred by the US Department of Health & Human Services (HHS).

Phase 3 trial of vorolanib intravitreal insert, using a tyrosine kinase inhibitor (TKI), will be evaluating for wet age-related macular degeneration (wet AMD).   

A Phase 3 randomised clinical trial has recruited of >400 patients in a seven-month period, driven by clinical and patient interest, according to the trial’s… Read More »Phase 3 trial of vorolanib intravitreal insert, using a tyrosine kinase inhibitor (TKI), will be evaluating for wet age-related macular degeneration (wet AMD).   

A research survey is the first to evaluate patient perspectives and considerations regarding the application of AI in the diagnosis of IRDs.

Researchers at the University College London, Institute of Ophthalmology, and Moorfields Eye Hospital, NHS Foundation Trust, UK, reported a study indicating that large disparities of… Read More »A research survey is the first to evaluate patient perspectives and considerations regarding the application of AI in the diagnosis of IRDs.

Clinical research on patients with infantile nystagmus syndrome (INS), across several inherited ocular diseases, may provide significant support for counselling and on-going clinical trials.   

Clinical researchers at the Department of Ophthalmology and the Vision Centre of Excellence, Akron Children’s Hospital, Ohio, have reported a molecular diagnostic rate of 41.5%… Read More »Clinical research on patients with infantile nystagmus syndrome (INS), across several inherited ocular diseases, may provide significant support for counselling and on-going clinical trials.   

Ashvattha Therapeutics has announced positive Phase 2 results for subcutaneous migaldendranib, delivered via a hydroxyl dendrimer for retinal vascular disease.

Ashvattha Therapeutics, based in Redwood City, California, have announced positive interim Phase 2 results for migaldendranib (MGB) and hydroxyl dendrimer, aimed to treat retinal vascular… Read More »Ashvattha Therapeutics has announced positive Phase 2 results for subcutaneous migaldendranib, delivered via a hydroxyl dendrimer for retinal vascular disease.

New study on a genome-wide association of central serous chorioretinopathy (CSC), varicose veins and glaucoma identifies a missense variant in PTPRB gene.

Researchers at the Institute for Molecular Medicine Finland (FIMM), University of Helsinki, and the Massachusetts Eye and Ear and Broad Institute of MIT and Harvard,… Read More »New study on a genome-wide association of central serous chorioretinopathy (CSC), varicose veins and glaucoma identifies a missense variant in PTPRB gene.